Ausgabe 4/2017
Special Issue: The Proteasome: An important player in tumor progression and a novel target for cancer therapy
Inhalt (13 Artikel)
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson, Paul G. Richardson
Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors
James J. Driscoll, Magen Brailey
Open Access
(Immuno)proteasomes as therapeutic target in acute leukemia
Jacqueline Cloos, Margot SF Roeten, Niels E Franke, Johan van Meerloo, Sonja Zweegman, Gertjan JL Kaspers, Gerrit Jansen
The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities
Wafik Zaky, Christa Manton, Claudia P. Miller, Soumen Khatua, Vidya Gopalakrishnan, Joya Chandra
Open Access
Proteasome-associated deubiquitinases and cancer
Arjan Mofers, Paola Pellegrini, Stig Linder, Pádraig D’Arcy
Open Access
Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents
Xin Chen, Qianqian Yang, Lu Xiao, Daolin Tang, Q. Ping Dou, Jinbao Liu
E3 ubiquitin ligases in cancer and implications for therapies
Dong Wang, Leina Ma, Bin Wang, Jia Liu, Wenyi Wei
Proteasome dysregulation in human cancer: implications for clinical therapies
Yulin Chen, Yanan Zhang, Xing Guo
Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing
Claire L. Soave, Tracey Guerin, Jinbao Liu, Q. Ping Dou
NON-THEMATIC REVIEW
Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers
Lon Wolf R. Fong, David C. Yang, Ching-Hsien Chen